NCRI 2017 | Rituximab vs. standard chemotherapy: which treatment benefits B-cell ALL patients more?

David Marks

Can patients with B-cell acute lymphoblastic leukemia (ALL) benefit more from using rituximab as part of their treatment compared to using standard chemotherapy alone? This is one question that Prof. David Marks, MBBS, PhD, FRACP, FRCPath, of University Hospitals Bristol NHS Foundation Trust, Bristol, UK, has investigated during the UKALL14 trial (NCT01085617). Speaking at the 2017 National Cancer Research Institute (NCRI) Conference in Liverpool, UK, Prof. Marks briefly talks about the primary endpoints of the trial and expresses his interest in finding out the results gathered.

Share this video